CU23740A1 - Método de obtención de una formulación de antígenos del virus de la hepatitis b - Google Patents
Método de obtención de una formulación de antígenos del virus de la hepatitis bInfo
- Publication number
- CU23740A1 CU23740A1 CU20090164A CU20090164A CU23740A1 CU 23740 A1 CU23740 A1 CU 23740A1 CU 20090164 A CU20090164 A CU 20090164A CU 20090164 A CU20090164 A CU 20090164A CU 23740 A1 CU23740 A1 CU 23740A1
- Authority
- CU
- Cuba
- Prior art keywords
- formulation
- antigens
- hbv
- cells
- stimulation
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 5
- 230000000638 stimulation Effects 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 239000002244 precipitate Substances 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La presente invención se relaciona con el campo de la inmunización terapéutica, específicamente con el empleo de una nueva formulación de antígenos del virus de la Hepatitis B (VHB) para la estimulación celular. La formulación está formada por precipitados en suspensión de los antígenos de la superficie (HBsAg) y de la nucleocápsida (HBcAg) del VHB. La formulación contiene a dichos antígenos como precipitados en suspensión de partículas de tallas inferiores a 500 nm y superiores a 500nm, en una mezcla donde la proporción entre las partículas de las tallas mencionadas está entre 50%-50% y 80%-20%, respectivamente. La selección de un rango de tallas de partículas permite que los niveles de estimulación de varios tipos celulares sea el máximo. Adicionalmente, se describe3 un método de estimulación celular con dicha formulación, y la posterior inmunización pasiva de pacientes con Hepatitis B crónica, basado en la máxima estimulación in vivo o in vitro de células heterólogas o autólogas (células dendríticas, células B y macrófagos). Las células estimuladas con esta formulación se transfieren a pacientes infectados crónicamente con el VHB.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20090164A CU23740A1 (es) | 2009-09-29 | 2009-09-29 | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
PCT/CU2010/000003 WO2011038701A1 (es) | 2009-09-29 | 2010-09-28 | Formulación de antigenos del virus de la hepatitis b para la estimulación celular seguida de la inmunización terapéutica |
US13/498,842 US20120308615A1 (en) | 2009-09-29 | 2010-09-28 | Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization |
EP10770699A EP2484343A1 (en) | 2009-09-29 | 2010-09-28 | Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization |
CN2010800489910A CN102665687A (zh) | 2009-09-29 | 2010-09-28 | 用于细胞刺激随后进行治疗性免疫的乙肝病毒抗原制剂 |
RU2012117233/10A RU2012117233A (ru) | 2009-09-29 | 2010-09-28 | Состав антигенов вируса гепатита в для клеточной стимуляции с последующей терапевтической иммунизацией |
JP2012531233A JP2013505971A (ja) | 2009-09-29 | 2010-09-28 | 治療上の免疫化後の細胞性刺激のためのb型肝炎ウイルス抗原製剤 |
CA2775794A CA2775794A1 (en) | 2009-09-29 | 2010-09-28 | Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization |
AU2010302740A AU2010302740A1 (en) | 2009-09-29 | 2010-09-28 | Hepatitis B virus antigen formulation for cell stimulation followed by therapeutic immunization |
BR112012007180A BR112012007180A2 (pt) | 2009-09-29 | 2010-09-28 | formulação dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b, métodos de obtenção de uma formulação dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b, de estimulação de células para a imunoterapia passiva e de imunização passiva de pacientes com hepatite b crônica e uso de uma formulação composta por precipitados em suspensão dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b |
KR1020127008797A KR20120080598A (ko) | 2009-09-29 | 2010-09-28 | 치료적 면역화반응이 따르는 세포 자극용 비형 간염 바이러스 항원의 제형 |
ZA2012/02768A ZA201202768B (en) | 2009-09-29 | 2012-04-16 | Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20090164A CU23740A1 (es) | 2009-09-29 | 2009-09-29 | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23740A1 true CU23740A1 (es) | 2011-12-28 |
Family
ID=43127828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20090164A CU23740A1 (es) | 2009-09-29 | 2009-09-29 | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120308615A1 (es) |
EP (1) | EP2484343A1 (es) |
JP (1) | JP2013505971A (es) |
KR (1) | KR20120080598A (es) |
CN (1) | CN102665687A (es) |
AU (1) | AU2010302740A1 (es) |
BR (1) | BR112012007180A2 (es) |
CA (1) | CA2775794A1 (es) |
CU (1) | CU23740A1 (es) |
RU (1) | RU2012117233A (es) |
WO (1) | WO2011038701A1 (es) |
ZA (1) | ZA201202768B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104043120B (zh) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
CN109219449B (zh) * | 2016-03-31 | 2022-08-30 | 遗传工程与生物技术中心 | 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 |
CN111450245A (zh) * | 2020-04-29 | 2020-07-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种乙型肝炎治疗疫苗及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22290A1 (es) | 1990-10-08 | 1995-01-31 | Cigb | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
US20010053365A1 (en) * | 1995-04-25 | 2001-12-20 | Smithkline Beecham Biologicals S.A. | Vaccines |
WO1998016238A2 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
CN1919341B (zh) * | 2005-08-24 | 2012-01-25 | 复旦大学 | 乙肝表面抗原-抗体复合物在制备对乙肝疫苗无应答或低应答预防制品中的用途 |
CN1981866B (zh) * | 2006-04-30 | 2011-04-06 | 解放军三○二医院生物治疗研究中心 | 新型慢性乙肝治疗性dc疫苗 |
WO2008104133A1 (es) * | 2007-02-28 | 2008-09-04 | Centro De Ingeniería Genética Y Biotecnología | Terapia combinada para el tratamiento de la hepatitis b crónica |
WO2009143524A2 (en) * | 2008-05-23 | 2009-11-26 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
-
2009
- 2009-09-29 CU CU20090164A patent/CU23740A1/es not_active IP Right Cessation
-
2010
- 2010-09-28 CN CN2010800489910A patent/CN102665687A/zh active Pending
- 2010-09-28 BR BR112012007180A patent/BR112012007180A2/pt not_active Application Discontinuation
- 2010-09-28 US US13/498,842 patent/US20120308615A1/en not_active Abandoned
- 2010-09-28 RU RU2012117233/10A patent/RU2012117233A/ru not_active Application Discontinuation
- 2010-09-28 WO PCT/CU2010/000003 patent/WO2011038701A1/es active Application Filing
- 2010-09-28 KR KR1020127008797A patent/KR20120080598A/ko not_active Application Discontinuation
- 2010-09-28 JP JP2012531233A patent/JP2013505971A/ja active Pending
- 2010-09-28 EP EP10770699A patent/EP2484343A1/en not_active Withdrawn
- 2010-09-28 CA CA2775794A patent/CA2775794A1/en not_active Abandoned
- 2010-09-28 AU AU2010302740A patent/AU2010302740A1/en not_active Abandoned
-
2012
- 2012-04-16 ZA ZA2012/02768A patent/ZA201202768B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120080598A (ko) | 2012-07-17 |
JP2013505971A (ja) | 2013-02-21 |
ZA201202768B (en) | 2012-12-27 |
AU2010302740A1 (en) | 2012-05-24 |
RU2012117233A (ru) | 2013-11-10 |
US20120308615A1 (en) | 2012-12-06 |
CA2775794A1 (en) | 2011-04-07 |
EP2484343A1 (en) | 2012-08-08 |
WO2011038701A1 (es) | 2011-04-07 |
CN102665687A (zh) | 2012-09-12 |
BR112012007180A2 (pt) | 2016-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087380A1 (es) | Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas | |
CL2018002528A1 (es) | Agentes anti virales de la hepatitis b. | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
ECSP12012067A (es) | Inhibidores del virus de la hepatitis c | |
PE20121526A1 (es) | Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c | |
CO6592102A2 (es) | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
MX2022013596A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
MX2020007227A (es) | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. | |
PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
JP2014508752A5 (es) | ||
BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
RU2015117251A (ru) | Новые соединения | |
AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
MX2014010482A (es) | Metodo para la preparacion de vacunas de celulas dendriticas. | |
UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
CO6321162A2 (es) | Una vacuna que comprende una cantidad inmunogenica de un antigeno en somastatina y un adyuvante | |
AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
PE20151086A1 (es) | COMPUESTOS DERIVADOS DE 5H-PIRROLO-[3,2-d]PIRIMIDIN-4-AMINA 2,6,7 TRISUSTITUIDOS O 2,7 DISUSTITUIDOS COMO INDUCTORES DEL INTERFERON HUMANO | |
AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
AR077225A1 (es) | Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza | |
CU23740A1 (es) | Método de obtención de una formulación de antígenos del virus de la hepatitis b | |
BR112012023285A2 (pt) | métodos para gerar células dendríticas carregadas de antígeno e para eliciar uma resposta imune em um mamífero, e, composição preservável | |
JP2018535191A5 (es) | ||
JP2014512391A5 (es) | ||
JP2019534307A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent | ||
FD | Lapse (for not paying fees) |